Primary Endpoint

Spexis AG

28/06/2021 06:06

June 28 (Reuters) - POLYPHOR AG  POLN.S :
    * PROVIDES UPDATE ON THE PHASE III FORTRESS STUDY OF
BALIXAFORTIDE
IN PATIENTS WITH ADVANCED HER2 NEGATIVE BREAST CANCER
    * CO-PRIMARY ENDPOINT OF STUDY OBJECTIVE RESPONSE RATE (ORR)
WAS
NOT MET
    * BOARD OF DIRECTORS IS UNDERGOING A STRATEGIC ASSESSMENT
REGARDING FUTURE OF COMPANY

Source text for Eikon:  ID:nEQHCR6Da 
Further company coverage:  POLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))